(Globe Newswire) Toronto — Avicanna Inc., a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products, invites interested parties to participate in a conference call with Aras Azadian, chief executive officer, and also Phil Cardella, chief financial ffficer where Mr. Azadian and Mr. Cardella will discuss the company’s Full Year 2023 financial results.
The company will file Full Year 2023 financial results after the close of market on April 1, 2024 and will host an earnings call at 8:30 am ET on April 2, 2024.
